Hemacare Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2012
2015
2016
2017
2018
Net Income before Extraordinaries
1,163.00
3,236.00
781.00
4,432.00
4,516
Depreciation, Depletion & Amortization
705.00
400.00
403.00
375.00
471
Other Funds
1,829.00
4,418.00
217.00
607.00
888
Funds from Operations
39.00
782.00
1,401.00
4,286.00
7,039
Changes in Working Capital
382.00
707.00
1,475.00
963.00
996
Net Operating Cash Flow
343.00
1,489.00
74.00
3,323.00
8,035
Capital Expenditures
316.00
200.00
257.00
543.00
Sale of Fixed Assets & Businesses
2.00
4,576.00
-
-
Purchase/Sale of Investments
-
-
107.00
428.00
Net Investing Cash Flow
543.00
4,376.00
150.00
115.00
Issuance/Reduction of Debt, Net
19.00
585.00
30.00
74.00
Net Financing Cash Flow
19.00
585.00
20.00
3,772.00
Net Change in Cash
905.00
2,302.00
244.00
6,980.00
Free Cash Flow
659.00
1,689.00
331.00
2,780.00
Deferred Taxes & Investment Tax Credit
-
-
-
1,128.00
1,164
Change in Capital Stock
-
-
10.00
3,846.00
Other Uses
229.00
-
-
-

About Hemacare

View Profile
Address
15350 Sherman Way
Van Nuys California 91406
United States
Employees -
Website http://www.hemacare.com
Updated 07/08/2019
HemaCare Corp. engages in the provision of bioresearch products and services for customer's research and cell therapy protocols. It offers human derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provides a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company was founded in 1978 and is headquartered in Van Nuys, CA.